NCT03184545 Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
| NCT ID | NCT03184545 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Northwell Health |
| Condition | Patellofemoral Pain Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2017-07-24 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 92 participants in total. It began in 2017-07-24 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of study is to evaluate the efficacy of the electrical muscle stimulation (EMS) device in patients with patellofemoral pain known as anterior knee pain. Usual treatment for it is physical therapy (PT). We want to evaluate and see if adding the electrical muscle stimulation will fasten the recovery and improved outcome in patellofemoral pain syndrome. Half of participants will receive EMS and PT while other half will receive PT only.
Eligibility Criteria
Inclusion Criteria: * Bilateral/unilateral anterior knee pain for more than 3 moths * Age of patient 18 to 40 years * At least 3 of the 4 following criteria present: pain associated with prolonged sitting with knees bend, pain with going downstairs, kneeling and squatting or sports activities * No h/o injury * No h/o surgery to the knee Exclusion Criteria: * H/o patellar dislocation or subluxation * Associated bursitis, tendinitis in periarticular area * Ligamentous problems * Intra-articular pathology * Pregnancy (patient reported pregnancy, in case of doubt patient will be referred to their OBG/GYN physician to exclude the pregnancy) * H/o knee surgery * Oral or intraarticular administration of steroid medication with in last 3 months * Patients with implanted devices like pacemaker
Contact & Investigator
Leon Popovitz, MD
PRINCIPAL INVESTIGATOR
Northwell Health
Frequently Asked Questions
Who can join the NCT03184545 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Patellofemoral Pain Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03184545 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 92 participants.
Is NCT03184545 currently recruiting?
Yes, NCT03184545 is actively recruiting participants. Contact the research team at orthodoc205@gmail.com for enrollment information.
Where is the NCT03184545 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT03184545 clinical trial?
NCT03184545 is sponsored by Northwell Health. The principal investigator is Leon Popovitz, MD at Northwell Health. The trial plans to enroll 92 participants.